BMJ editorial warns rapid growth in private testosterone prescribing risks overtreatment
- Experts writing in The BMJ warn that private testosterone prescribing in the UK is expanding fast.
- They say treatment may reach men with non-specific symptoms and borderline test results.
- NHS community dispensing of testosterone rose by 52% between 2020/21 and 2024/25.
- The authors call for national reporting of private testosterone prescriptions.
In an editorial in The BMJ, Stephen Atkin and Eric Kilpatrick warn that the fast growth of private testosterone prescribing in the UK risks extending treatment beyond men with a clearly defined need to people with non-specific symptoms and borderline test results, for whom the balance of benefit and long-term risk is less certain.
What the figures show
NHS figures show that community dispensing of testosterone rose by 52% between 2020/21 and 2024/25. Private prescriptions are not recorded nationally, so their scale is unknown. The authors point to several signs of rapid growth: many new private and online clinics, subscription models and heavy marketing on social media.
Also read: Finnish study: animal and plant protein show opposite links with testosterone in men
Why diagnosis matters
Falling testosterone and libido are natural parts of ageing, and up to a fifth of men over 50 may report symptoms of deficiency, yet fewer than 1% are treated on the NHS. A correct diagnosis takes time and repeated blood tests. The authors warn that fast-access models built around non-specific symptoms risk unnecessary lifelong treatment.
Long-term monitoring
Testosterone therapy carries longer-term risks, such as heart and kidney problems, that need ongoing monitoring. The authors expect much of this work to fall on NHS general practitioners, often without any formal shared-care agreement. They also raise concerns about off-label testosterone prescribing to women for low libido after menopause. They stress that testosterone remains valuable for carefully selected patients and call for a national reporting framework for private prescribers and pharmacies.
Source: BMJ Group
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What does the BMJ editorial say about private testosterone prescribing?
The BMJ editorial warns that rapid growth in private testosterone prescribing may extend treatment to men with non-specific symptoms and borderline results, for whom benefits and long-term risks are less certain.
How much has NHS testosterone dispensing increased?
According to the BMJ editorial, NHS community dispensing of testosterone increased by 52% between 2020/21 and 2024/25.
Why is diagnosing low testosterone complicated?
Diagnosing low testosterone takes time and repeated blood tests, because falling testosterone and libido are also natural parts of ageing.
What long-term risks of testosterone therapy need monitoring?
The BMJ authors list heart and kidney problems among the longer-term risks of testosterone therapy that need ongoing monitoring.
What do the BMJ authors recommend about private testosterone prescriptions?
The BMJ authors recommend a national reporting framework for private testosterone prescribers and dispensing pharmacies to close the evidence gap.


